Seizure Outcomes With Cannabidiol (CBD) in Pediatric Versus Adult Patients With Lennox-Gastaut Syndrome (LGS) and Dravet Syndrome (DS): Subgroup Analysis of BECOME, a Caregiver Survey

Abstract number : 3.428
Submission category : 7. Anti-seizure Medications / 7E. Other
Year : 2022
Submission ID : 2232964
Source : www.aesnet.org
Presentation date : 12/5/2022 12:00:00 PM
Published date : Nov 22, 2022, 05:29 AM

Authors :
Timothy Saurer, PhD – Jazz Pharmaceuticals; Anne Berg, PhD – Northwestern University Feinberg School of Medicine; Tracy Dixon-Salazar, PhD – Lennox-Gastaut Syndrome (LGS) Foundation; Mary Anne Meskis, - – Dravet Syndrome Foundation; Sherry Danese, MS, MBA – Outcomes Insights; Ngoc Minh Le, MD – Jazz Pharmaceuticals; M. Scott Perry, MD – Cook Children’s Medical Center

This is a Late Breaking abstract

Rationale: BEhavior, Cognition, and More with Epidiolex® (BECOME) was a global outcomes survey of caregivers of patients with LGS or DS to characterize and quantify seizure and nonseizure outcomes of the FDA-approved CBD treatment. In the primary analysis, a substantial proportion of caregivers reported improvements in seizure frequency and severity. Although onset of LGS and DS is usually in infancy or childhood, they are lifelong diseases with symptoms that evolve over time, emphasizing the need to understand effects of CBD in pediatric vs adult patients. Thus, we evaluated the seizure and nonseizure outcomes in patients aged < 18 years vs. ≥18 years. This first abstract reports the seizure outcomes.
Anti-seizure Medications